Anavex Successfully Closes $10 Million Financing to Initiate Phase 1b/2a Alzheimer’s Clinical Trial

New York, NY — March 19, 2014 — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQB: AVXL), a clinical stage biopharmaceutical company developing novel drug candidates to treat Alzheimer’s, diseases of the central nervous system (CNS) and various types of cancer, announced today that it has closed, as previously announced on March 13, 2014,…